PAX2 Antibody

What is PAX2 and what are its primary biological functions in research models?

PAX2 is a transcription factor involved in multiple developmental processes, particularly in the nervous and excretory systems. It plays critical roles in the development of the kidney and urogenital tract, the optic stalk, ear, midbrain-hindbrain junction, and spinal cord . In adult tissues, PAX2 continues to regulate various cellular processes, including the expression of transmembrane ion and water channels in the renal medulla .

PAX2 has gained significant research interest because:

• It functions as a developmental regulator in the nervous system and kidney formation

• It demonstrates oncogenic properties in certain cancers

• It acts as a transcriptional repressor for specific target genes

• Its expression patterns change during pathological processes

What are the recommended antibody dilutions and protocols for PAX2 immunodetection?

Based on extensive laboratory testing, the following protocols have shown optimal results:

For immunohistochemistry, the Vectastain ABC kit with a liquid DAB-plus substrate kit has shown excellent results for PAX2 detection . When performing multiplex staining, PAX2 can be effectively co-stained with other markers such as FOXJ1 (ciliated cell marker) .

How should tissue fixation and processing be optimized for PAX2 immunostaining?

Tissue fixation significantly impacts PAX2 antibody performance. Based on researcher experiences:

• Light fixation is critical - excessive fixation can mask epitopes

• Optimal protocol involves 1-2 hours post-fix after paraformaldehyde (PFA) perfusion

• For paraffin-embedded tissues, standard antigen retrieval methods are recommended

• For frozen sections, brief fixation in 4% PFA followed by permeabilization yields best results

A common pitfall is overfixation, which can lead to false-negative results even when PAX2 is present in the sample.

Which PAX2 antibodies have demonstrated superior performance in published research?

Several antibodies have been validated across multiple studies:

• Rabbit anti-PAX2 antibody from Thermo Fisher Scientific (Cat#716000) demonstrates excellent specificity in neural tissues

• Cell Signaling Technology PAX2 Antibody #9666 shows consistent results in Western blotting and immunoprecipitation applications

• For immunohistochemistry applications in studying endometrial tissues, the PAX2 antibody used by Mutter et al. has shown clear distinction between positive and negative cells

When selecting an antibody, researchers should consider the intended application, as some antibodies perform better in certain contexts than others.

How can PAX2 antibodies be utilized in cancer research and what are the key findings?

PAX2 has emerged as an important factor in several cancer types with distinct roles:

Breast Cancer:

• PAX2 is activated by estradiol in luminal breast cancer cells

• It functions as a negative regulator of cell invasiveness in luminal breast cancer models

• PAX2 negatively regulates ERBB2 expression, a pro-invasion and pro-metastatic gene

• Overexpression of PAX2 inhibits estradiol-induced cellular proliferation and decreases invasive capacity

Prostate Cancer:

• PAX2 functions as an oncogene that represses human Beta Defensin-1 (hBD1) expression

• This repression occurs through binding of the PAX2 homeodomain to the hBD1 promoter

• Knockdown of PAX2 results in re-expression of hBD1 and subsequent cancer cell death

• These findings suggest PAX2 as a potential therapeutic target for prostate cancer treatment

Endometrial Cancer:

• PAX2 loss is observed early in endometrial hyperplasia

• Loss becomes more frequent and complete with increasing severity of hyperplasia

• PAX2 immunostaining has potential diagnostic and prognostic value in endometrial pathology

What methodologies are recommended for quantifying PAX2 expression in experimental models?

For accurate quantification of PAX2 expression:

Scoring System for Immunohistochemistry:
The following validated scoring system has been used in pathology research:

• Complete loss (0% cells staining)

• Partial loss (1-75% cells staining)

• Minimal to no loss (76-100% cells staining)

For more detailed analysis, a five-tier scoring system can be employed:

Important Considerations:

• Only nuclear staining should be considered positive for PAX2

• Both staining intensity and percentage of positive cells should be recorded

• Adjacent normal tissue should be used as an internal control when possible

How can PAX2 antibodies be effectively incorporated into multiplex immunofluorescence studies?

When designing multiplex studies with PAX2 antibodies:

• Compatible marker combinations:

  • PAX2 with FOXJ1 for distinguishing non-ciliated from ciliated cells

  • PAX2 with VGLUT2 for studying neuronal subtypes

  • PAX2 with PAX8 for renal development studies

• Optimized protocol for co-staining:

  • Begin with antigen retrieval optimized for the most sensitive antibody

  • Apply primary antibodies sequentially rather than in cocktail format

  • Use secondary antibodies with minimal cross-reactivity

  • Include appropriate blocking steps to minimize background

• Example multiplex application:
  In studies of spinal dorsal horn neurons, PAX2 has been successfully co-stained with tdTomato and VGLUT2, revealing that approximately 70% of tdTomato-positive neurons co-express PAX2, indicating their inhibitory nature .

What are common technical challenges with PAX2 immunostaining and recommended troubleshooting approaches?

A particularly common issue reported by researchers is difficulty in distinguishing specific from non-specific staining. Using appropriate controls and comparative antibody testing is essential for resolving this challenge.

How should experiments be designed to study PAX2 function in development and disease models?

For robust experimental design:

• Genetic approaches:

  • Conditional knockout models targeting PAX2 in specific tissues

  • Temporal control of PAX2 expression using inducible systems

  • CRISPR-Cas9 editing to introduce specific mutations found in human diseases

• Expression manipulation strategies:

  • siRNA knockdown of PAX2 has been successfully employed to study its role in cancer cell survival

  • Overexpression systems using PAX2 cDNA to assess functional consequences

  • Assessment of downstream effects on target genes like hBD1 and ERBB2

• Readout assays:

  • Cell invasion assays to measure metastatic potential

  • Proliferation assays to assess growth regulatory functions

  • Apoptosis assays (PARP cleavage, nuclear morphology)

  • Luciferase reporter assays to study promoter regulation

What are the critical controls required for PAX2 antibody-based studies?

Proper controls are essential for reliable PAX2 antibody research:

• Positive controls:

  • Tissues known to express PAX2 (developing kidney, specific neuronal populations)

  • Cell lines with validated PAX2 expression

  • Adjacent normal tissue when studying pathological samples

• Negative controls:

  • Omission of primary antibody

  • Isotype control antibodies (rabbit IgG for rabbit-derived PAX2 antibodies)

  • PAX2 knockout or knockdown samples when available

  • Tissues known to be PAX2-negative (specific mature cell types)

• Validation controls:

  • Chromatin immunoprecipitation (ChIP) experiments to confirm antibody specificity

  • Western blot confirmation of the correct molecular weight (47 kDa)

  • Dual staining with antibodies targeting different epitopes of PAX2

How do PAX2 expression patterns vary across different pathological conditions?

Understanding PAX2 expression changes in disease contexts is critical for interpretation:

Endometrial Pathology:

• Normal endometrium: Consistent nuclear PAX2 expression

• Simple hyperplasia: Early evidence of PAX2 loss in some cells

• Complex hyperplasia: Increasing frequency of PAX2 loss

• Atypical hyperplasia: More extensive and complete PAX2 loss

• Endometrial carcinoma: Frequently shows complete PAX2 loss

Renal Pathology:

• PAX2 is critical for regulating urea transporters and aquaporins

• Alteration of PAX2 expression affects water and solute homeostasis

• PAX2 and PAX8 cooperatively regulate these transporters in the renal medulla

Neural Tissues:

• In spinal dorsal horn, PAX2 expression identifies inhibitory neurons

• Approximately 70% of inhibitory neurons in this region express PAX2

• This pattern is important for understanding neural circuit organization

How are PAX2 antibodies being used to explore the relationship between development and cancer?

Recent research has revealed intriguing connections between PAX2's developmental roles and its functions in cancer:

• PAX2 normally functions in tissue development and differentiation

• Inappropriate activation in adult tissues may contribute to oncogenesis

• In breast cancer, PAX2 appears to maintain a more differentiated, less invasive phenotype

• Conversely, in prostate cancer, PAX2 acts as an oncogene by suppressing hBD1

This dual role makes PAX2 an interesting target for studying the relationship between development and cancer. PAX2 antibodies are being used to:

• Map expression patterns across developmental stages and compare with malignant tissues

• Identify cells of origin for specific cancer types

• Study how developmental pathways are hijacked during oncogenesis

What novel therapeutic approaches are targeting PAX2, and how can antibodies facilitate this research?

PAX2-targeted therapies are being explored in several contexts:

• Prostate cancer:

  • siRNA knockdown of PAX2 induces hBD1-mediated cell death

  • This approach could potentially be developed into a therapeutic strategy

• Breast cancer:

  • PAX2 overexpression reduces invasiveness of breast cancer cells

  • Strategies to enhance PAX2 activity could potentially reduce metastatic potential

• Combined approaches:

  • For ERα-negative breast cancers, combined therapies to restore ERα expression and overexpress PAX2 might interfere with metastatic progression

PAX2 antibodies facilitate this research by:

• Enabling screening of potential therapeutic compounds that modulate PAX2 expression

• Monitoring treatment effects in preclinical models

• Identifying patient populations most likely to benefit from PAX2-targeted approaches

How can chromatin immunoprecipitation (ChIP) with PAX2 antibodies advance understanding of PAX2 target genes?

ChIP experiments using PAX2 antibodies have revealed important insights:

• PAX2 directly binds to the hBD1 promoter through its homeodomain

• The binding sequence has been identified using ChIP followed by PCR amplification

• The primer set (5′-TAGGGGTACCCCCATGTGACTGCTGACT-3′ and 5′-TCTGCATAAGGGGAGAGATGAGA-3′) successfully amplifies the 160-bp fragment of the hBD1 promoter containing the PAX2 consensus sequence

Future ChIP-seq studies using validated PAX2 antibodies could:

• Identify the complete set of PAX2 target genes in different cell types

• Reveal how PAX2 binding patterns change during development or disease progression

• Uncover cooperative interactions with other transcription factors

• Provide a more comprehensive understanding of PAX2's role in gene regulation networks

How can researchers validate PAX2 antibody specificity for their particular application?

A systematic approach to antibody validation includes:

• Western blot validation:

  • Confirm single band at expected molecular weight (47 kDa)

  • Test in positive control samples (tissues/cells known to express PAX2)

  • Include negative controls (tissues/cells known to lack PAX2 expression)

• Immunostaining pattern analysis:

  • Verify expected nuclear localization

  • Compare staining pattern with published literature

  • Assess staining in tissues with known positive and negative regions

• Genetic validation:

  • Test in PAX2 knockout or knockdown models

  • Compare multiple antibodies targeting different epitopes

  • Perform peptide competition assays

• Functional validation:

  • ChIP experiments to confirm binding to known PAX2 target genes

  • Correlation of staining with functional readouts

What are the most reliable methods for distinguishing true PAX2 signal from non-specific background?

Researchers have identified several approaches to ensure signal specificity:

• Careful antibody titration:

  • Even at high dilutions (1:2000), some antibodies may show non-specific binding

  • Perform careful concentration curves to determine optimal dilution

  • Compare multiple antibodies from different sources

• Signal characteristics:

  • Authentic PAX2 signal should be exclusively nuclear

  • Signal intensity should correlate with expected expression levels

  • Pattern should be consistent with known PAX2 biology

• Comparative analysis:

  • The rabbit anti-PAX2 antibody from Thermo Fisher Scientific (Cat#716000) has shown superior specificity compared to some alternatives

  • Use this as a benchmark when testing new antibodies

• Dual methodologies:

  • Confirm immunostaining results with complementary techniques (Western blot, qPCR)

  • Use orthogonal methods to validate key findings

By addressing these technical considerations, researchers can ensure the reliability and reproducibility of their PAX2 antibody-based studies, contributing to our understanding of this important developmental regulator and its roles in disease.